Vitamin D (25-OH): blood level, cutoff ranges and follow-up tests

What 25-hydroxyvitamin D is and what it stands for

25-hydroxyvitamin D, or 25(OH)D for short, is the main storage form of vitamin D circulating in the blood. The liver makes it from cholecalciferol (D3) and ergocalciferol (D2), which come either from the body’s own production or from food. The level reflects the balance between intake, production and use. Persistently low levels can point to an inadequate supply that affects calcium balance, bone remodeling and muscle function.

How vitamin D is activated in two steps

The skin produces vitamin D when UVB light strikes 7-dehydrocholesterol. Foods also supply vitamin D, for example oily fish, fortified milk or plant-based drinks, and egg yolk. These forms of vitamin D travel to the liver, which converts them into 25(OH)D. That is the form measured in blood tests, because it is stable and has a half-life of about two to three weeks.

Enzymes in the kidneys then convert 25(OH)D into 1,25-dihydroxyvitamin D (calcitriol). This active hormone is what helps the gut absorb calcium and phosphate, keeps parathyroid hormone (PTH) in check and coordinates bone turnover. It works as a feedback loop: low calcium raises PTH, which speeds up the kidney’s conversion step. When there is enough calcium, PTH falls. A 25(OH)D measurement therefore does not capture the active hormone, 1,25-dihydroxyvitamin D. The conversion in the kidneys is regulated separately, and PTH and kidney function matter for interpreting it.

Season, latitude, skin pigmentation, age and how much skin is covered by clothing all change production. Darker skin contains more melanin, which is protective but reduces UVB-driven vitamin D synthesis. With age, the skin makes fewer precursors. A higher body mass index is often linked to lower 25(OH)D, probably because the vitamin is spread over a larger body volume and stored in fat tissue. Acute illness and inflammation can temporarily lower the measured 25(OH)D level through shifts in vitamin D-binding protein and fluid balance. And because most tests measure total 25(OH)D (bound plus free), changes in binding proteins can affect results without reflecting any real change in how much is available to tissues.

The lab method matters too: different tests do not always agree. Some immunoassays do not fully detect D2. High-dose biotin can interfere with certain methods. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is considered the reference approach for accuracy and for telling D2 and D3 apart. The trend over time and the medical context say more than a single isolated result.

Which vitamin D levels count as low, sufficient or high?

Reference intervals are built from population data. Expert groups do not fully agree on cutoffs, partly because outcomes vary with age, baseline health and what is measured alongside 25(OH)D. The National Academy of Medicine has emphasized that levels around 20 ng/mL (50 nmol/L) meet the bone health needs of most people, with clear deficiency below 12 ng/mL (30 nmol/L). The Endocrine Society previously used 20 ng/mL as the deficiency threshold and considered higher levels sufficient for many people, while newer guidelines move away from uniform targets and routine screening in low-risk adults. The source article also gives cutoff ranges of below 12 to 20 ng/mL for deficiency and 30 ng/mL and above for sufficiency. These categories are not uniform and should not be read as a universal target. Labs also differ in calibration and units: to convert ng/mL to nmol/L, multiply the value by 2.5.

Sufficient 25(OH)D

A result in the sufficient range reflects enough substrate for the kidney’s activation step and supports normal calcium absorption and bone remodeling. In people without documented deficiency, though, a sufficient level does not mean that more supplementation brings wide-ranging benefits. In the VITAL trial, supplementation in mostly healthy adults reduced neither major cardiovascular events nor the overall number of new cancer cases. Some meta-analyses suggest a slight reduction in cancer mortality with vitamin D supplementation, but not in new cancer cases, and the observed effect is small. Pooled analyses suggest a slight reduction in acute respiratory infections with regular dosing, especially in people who were deficient at the start of the study, but the effects vary. The clearest case is for correcting a proven deficiency.

High 25(OH)D

Most high 25(OH)D results come from taking more vitamin D than the body needs over a long period. The body has protective mechanisms, but persistently high levels can come with raised calcium and, in rare cases, symptoms such as nausea or kidney stones. Calcium, PTH and kidney function are also important for interpreting the result.

Less commonly, granulomatous diseases such as sarcoidosis increase conversion into the active hormone, which can lead to high calcium even when 25(OH)D is not extreme. Lab artifacts are another issue: some immunoassays can show falsely high values if large amounts of biotin were taken within a day before the test, and cross-reactivity differs between platforms. If results do not fit the other lab values or the symptoms, confirmation by LC-MS/MS can clear things up.

Low 25(OH)D

Low levels often come from little sun exposure, low dietary vitamin D intake or seasonal variation. Skin pigmentation plays a part: more melanin means less production in the skin for the same sun exposure. Latitude and clothing also affect production. A higher BMI generally correlates with lower 25(OH)D for a given intake and sun exposure, reflecting distribution over a larger body volume.

Absorption and metabolism matter as well. Celiac disease, inflammatory bowel disease, pancreatic insufficiency and the aftermath of bariatric surgery can impair absorption. Liver disease can reduce conversion into 25(OH)D. Certain medications, including some anti-seizure drugs, rifampicin and glucocorticoids, increase vitamin D breakdown through liver enzymes. Chronic kidney disease affects the activation step, so 1,25-dihydroxyvitamin D falls and PTH rises even when 25(OH)D is only slightly low.

Life stage can change the interpretation. Older adults synthesize less in the skin. During pregnancy, binding proteins and active vitamin D rise, while total 25(OH)D may not change much, so context matters. In people with a deficiency, improving vitamin D status together with enough calcium supports bone mineralization and reduces osteomalacia in adults. A single low value does not automatically explain symptoms. What counts are the symptoms, the accompanying lab values and, where relevant, whether the value stays low on a repeat measurement.

Why your vitamin D level fluctuates

Several physical and external factors influence 25(OH)D in addition to deliberate intake.

UVB seasonality, latitude and clothing: synthesis in the skin drops sharply in winter at northern latitudes and is reduced further by covering clothing, indoor work and sunscreen use. This is the main reason for the seasonal dip most people experience.
Skin pigmentation: melanin absorbs UVB radiation, which protects against UV damage but slows vitamin D synthesis. People with darker skin need longer sun exposure to produce comparable amounts of 25(OH)D.
Body mass and fat distribution: a higher BMI is linked to lower circulating 25(OH)D, probably because vitamin D is fat-soluble and spreads through a larger volume of fat tissue, which lowers the concentration measured in blood.
Impaired absorption in the gut: celiac disease, inflammatory bowel disease, pancreatic insufficiency and the aftermath of bariatric surgery reduce intestinal absorption of vitamin D from food and supplements.
Hepatic 25-hydroxylation: liver disease can impair the conversion of vitamin D precursors into 25(OH)D and lower measured levels even when intake is adequate.
Chronic kidney disease: CKD reduces the kidney’s ability to convert 25(OH)D into the active hormone 1,25-dihydroxyvitamin D, which leads to a rise in PTH even when 25(OH)D is only slightly low. A low 25(OH)D result in the setting of CKD can point both to depleted stores and to impaired activation.
Medications: certain antiepileptic drugs, rifampicin and glucocorticoids speed up vitamin D breakdown through liver enzymes and lower 25(OH)D over time.
Magnesium status: magnesium is a cofactor for the hydroxylase enzymes that convert vitamin D into 25(OH)D and then into the active hormone. A lasting magnesium deficiency can impair vitamin D metabolism and blunt the response to supplementation.
Test method and biotin interference: LC-MS/MS is the reference standard and accurately distinguishes D2 from D3. Some immunoassays do not fully detect D2 or are prone to interference from high-dose biotin (over 5 mg/day), which can produce falsely raised results. Acute illness and inflammation can also temporarily lower measured 25(OH)D through shifts in vitamin D-binding protein.

Which lab values help with interpretation

25(OH)D is easier to interpret alongside other markers of mineral balance.

Calcium: calcium is the primary downstream indicator of vitamin D’s action. A low 25(OH)D level with falling calcium and rising PTH points to secondary hyperparathyroidism caused by vitamin D deficiency, the clearest clinical signal that a deficiency is affecting mineral balance.
Magnesium: magnesium is a cofactor for the hydroxylase enzymes that convert vitamin D into 25(OH)D and then into the active hormone. A lasting magnesium deficiency can impair vitamin D metabolism and blunt the response to supplementation. That makes it a useful check when 25(OH)D does not rise as expected.
eGFR: chronic kidney disease reduces the production of 1,25-dihydroxyvitamin D even when 25(OH)D is adequate. eGFR helps clarify whether a low value reflects depleted stores or impaired activation, which have different clinical implications.
Vitamin K: vitamin K activates osteocalcin and matrix Gla protein, proteins involved in bone metabolism and calcium regulation that work together with vitamin D-dependent processes. The source article describes a combined deficiency of both vitamins as a possible added strain on bone metabolism. What this means for testing and for taking them together has to be assessed separately.
Alkaline phosphatase (ALP): bone-specific ALP rises with increasing bone turnover when vitamin D is very low. A raised ALP together with low 25(OH)D points to the accelerated remodeling that comes before osteomalacia, and gives clinical weight to a result that would otherwise be an isolated low value.

When a follow-up test can make sense

25(OH)D has a half-life of about two to three weeks, and RCT data show that a new steady state is reached about 8 to 12 weeks after a dose change. An earlier measurement may still capture the adjustment phase rather than a stable new level.

After starting or changing a supplement dose: the source article suggests a check after 12 weeks to assess the full response.
Annual seasonal check: a blood draw at the end of winter is useful for anyone with risk factors (indoor work, northern latitude, darker skin, malabsorption or medications that speed up vitamin D breakdown) to catch the seasonal low point before it causes symptoms.

For a meaningful comparison, use the same lab and the same method where possible. LC-MS/MS is the reference standard; switching between immunoassay platforms can produce apparent changes that reflect differences in method rather than biology. A morning blood draw under consistent conditions reduces day-to-day variation. For biotin intake above 5 mg per day, the source article mentions a break of at least 48 hours before the blood draw. Whether to pause, and for how long, should be clarified with the lab or the treating practice based on the product and the test method.

When a vitamin D result calls for follow-up

The U.S. Preventive Services Task Force has concluded that the evidence is insufficient to recommend routine screening in adults without symptoms. Testing is therefore most useful when there is a clinical question, a change in health status or a need to track the course of treatment. A result outside the sufficient range is a reason to look at the whole picture: symptoms, related markers (calcium, ALP, eGFR, magnesium), medications and whether the pattern persists on repeat testing.

A very low result combined with raised ALP, rising PTH or falling calcium is a finding that a doctor should assess, especially in older adults, people with malabsorption or those taking medications that speed up vitamin D breakdown. A high result, particularly with raised calcium, also warrants follow-up to rule out excessive intake or a granulomatous disease driving excessive activation.

Vitamin D levels change with the seasons, habits and illness. A well-founded baseline measurement and later checks can make a trend visible. Calcium, eGFR and magnesium help put mineral balance in context. Which tests are actually needed depends on the medical question.

Frequently asked questions

What does a 25-hydroxy vitamin D test measure?

The 25-hydroxy vitamin D (25-OH-D) test measures the primary storage form of vitamin D in the blood. The value reflects both dietary intake and sun-driven synthesis and is the most accurate clinical marker of overall vitamin D status. Results are reported in ng/mL or nmol/L, depending on the lab.

What is a healthy vitamin D level?

Some clinical guidelines define sufficient vitamin D as a 25-OH-D level of 30 ng/mL or more (75 nmol/L). Values between 20 and 29 ng/mL are considered insufficient in some recommendations, while values below 20 ng/mL indicate deficiency. Some functional medicine practices aim for 40 to 60 ng/mL, although optimal targets remain debated.

Why does vitamin D matter for health beyond bones?

Vitamin D acts more like a hormone than a vitamin, since its receptors are found in almost every cell type, including immune cells, muscle and the brain. Adequate levels are associated with healthy immune regulation, mood stability, muscle function and cardiovascular health, functions that go far beyond its well-known role in calcium absorption.

What causes low vitamin D levels?

Common causes include limited sun exposure (especially at northern latitudes or when spending most of the time indoors), darker skin pigmentation (which reduces synthesis in the skin), low vitamin D intake, obesity (vitamin D binds in fat tissue) and conditions that impair fat absorption, such as Crohn’s disease or celiac disease.

What symptoms can occur with vitamin D deficiency?

Vitamin D deficiency often causes no symptoms, especially at borderline levels. When symptoms do occur, they can include fatigue, muscle weakness, bone pain and low mood. Because these overlap with many other conditions, a blood test can clarify vitamin D status. On its own, though, it does not prove that a low value is causing the symptoms.

How can I raise my vitamin D level?

The most common approaches include daily D3 supplementation (the dose depends on baseline levels and your doctor’s advice), sunlight on uncovered arms and legs (the source article mentions 15 to 30 minutes at midday, which is not a blanket recommendation that is safe for all skin types and UV conditions), and eating vitamin D-rich foods such as oily fish and egg yolk. The source article discusses K2 in addition to D3 as a possible support for calcium regulation. A general recommendation cannot be derived from this mechanism alone.

How often should I test my vitamin D level?

For a known deficiency where supplementation has started, the source article mentions a follow-up measurement after 3 months. It also suggests checks once or twice a year, especially at the end of winter, and more frequent measurements when gut absorption is impaired. This is partly at odds with the caution about general screening described above: testing intervals should be based on the specific risk and the need for treatment.

Does vitamin D affect immune function?

Vitamin D plays a direct role in immune regulation. It modulates both innate and adaptive immune responses and helps the body mount appropriate responses without excessive inflammation. Findings from several studies link adequate vitamin D levels with more balanced immune activity, although supplementation alone should not be seen as a substitute for comprehensive medical care.

Sources and references

Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Gordon D, Copeland T, D’Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE, VITAL Research Group (2019). Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. The New England journal of medicine, 380(1), 33-44. https://doi.org/10.1056/NEJMoa1809944 Publication

Jolliffe DA, Camargo CA, Jr., Sluyter JD, Aglipay M, Aloia JF, Ganmaa D, Bergman P, Bischoff-Ferrari HA, Borzutzky A, Damsgaard CT, Dubnov-Raz G, Esposito S, Gilham C, Ginde AA, Golan-Tripto I, Goodall EC, Grant CC, Griffiths CJ, Hibbs AM, … Martineau AR (2021). Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials. The lancet. Diabetes & endocrinology, 9(5), 276-292. https://doi.org/10.1016/S2213-8587(21)00051-6 Publication

Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, Dubnov-Raz G, Esposito S, Ganmaa D, Ginde AA, Goodall EC, Grant CC, Griffiths CJ, Janssens W, Laaksi I, Manaseki-Holland S, Mauger D, Murdoch DR, Neale R, … Camargo CA, Jr. (2017). Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ, 356, i6583. https://doi.org/10.1136/bmj.i6583 Publication

US Preventive Services Task Force, Krist AH, Davidson KW, Mangione CM, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Epling JW, Jr., Kubik M, Li L, Ogedegbe G, Owens DK, Pbert L, Silverstein M, Stevermer J, Tseng CW, Wong JB (2021). Screening for Vitamin D Deficiency in Adults: US Preventive Services Task Force Recommendation Statement. JAMA, 325(14), 1436-1442. https://doi.org/10.1001/jama.2021.3069 Publication

Demay MB, Pittas AG, Bikle DD, Diab DL, Kiely ME, Lazaretti-Castro M, Lips P, Mitchell DM, Murad MH, Powers S, Rao SD, Scragg R, Tayek JA, Valent AM, Walsh JME, McCartney CR (2024). Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism, 109(8), 1907-1947. https://doi.org/10.1210/clinem/dgae290 Publication